AQST
Aquestive Therapeutics, Inc.
Next earnings Aug 10, 2026 (after close) · consensus $-0.11 EPS, $11.6M rev
Last earnings -0.7% on 2026-05-13
$4.39
▼ -1.68%$4.39▲ +35.08%
over 1Y
L $2.95EODHDH $7.49
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-1.7%
1W-7.0%
1M+9.7%
3M+9.2%
YTD-31.9%
1Y+35.1%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 15 analysts
Buy
Conservative balance sheet (liabilities/equity -5.77x); but revenue fell -22.6% YoY.
Aquestive Therapeutics, Inc. shows $44.5M in FY2025 revenue (-22.6% YoY), a -188.1% net margin.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $50.8M | $47.7M | $50.6M | $57.6M | $44.5M |
| Gross profit | — | — | — | — | — |
| Operating income | -$34.7M | -$42.1M | -$15.1M | -$30.8M | -$71.1M |
| Net income | -$70.5M | -$54.4M | -$7.87M | -$44.1M | -$83.8M |
| Diluted EPS | -$1.85 | -$1.12 | -$0.13 | -$0.51 | -$0.78 |
| Net margin | -138.8% | -114.1% | -15.6% | -76.7% | -188.1% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$460M
EV / EBITDA—
EV / Sales10.3
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-15.6%
FCF yield-9.9%
Quality & risk
ROIC (est.)—
Free cash flow-$53.0M
Total debt$45.0M
Net cash$76.2M
Altman Z-Score-2.67 distress
Piotroski F-Score2/8
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+23.4%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — agreement terminated (2026-05-13). Worth a closer look.
- S-3 Shelf registration (potential raise)2026-06-26
- 8-K Shareholder vote2026-06-10
- 8-K Agreement terminated2026-05-13
- 10-Q Quarterly report2026-05-13
- DEF 14A Proxy statement2026-04-24
- 8-K Reg FD disclosure2026-03-30
- 8-K Officer / director change2026-03-20
- 8-K Material agreement2026-03-04
- 10-K Annual report2026-03-04
Recent filings
all on EDGAR ↗S-3Filing2026-06-26open ↗4Period ending 2026-06-232026-06-24open ↗144Filing2026-06-23open ↗4Period ending 2026-06-152026-06-16open ↗144Filing2026-06-15open ↗4Period ending 2026-06-102026-06-12open ↗4Period ending 2026-06-102026-06-12open ↗4Period ending 2026-06-102026-06-12open ↗4Period ending 2026-06-102026-06-12open ↗4Period ending 2026-06-102026-06-12open ↗4Period ending 2026-06-102026-06-12open ↗8-KPeriod ending 2026-06-102026-06-10open ↗
Frequently asked
- Is Aquestive Therapeutics, Inc. (AQST) a buy?
- AQST currently carries a Avoid rating with 4/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity -5.77x); but revenue fell -22.6% YoY.
- What is Aquestive Therapeutics, Inc.'s quality score?
- AQST scores 23.176470588235293/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001398733, latest 10-Q filed 2026-05-13) · EODHD · as of 6/26/2026, 5:53:28 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.